Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector.

Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector.

Choroideremia is an outer retinal degeneration with a characteristic clinical appearance that was first described in the nineteenth century. The disorder begins with reduction of night vision and gradually progresses to blindness by middle age. The appearance of the fundus in sufferers is recognizab...

Bibliografski detalji
Glavni autori:	Barnard, A, Groppe, M, Maclaren, R
Format:	Journal article
Jezik:	English
Izdano:	2014

Slični predmeti

Choroideremia: molecular mechanisms and development of AAV gene therapy
od: Patrício, M, i dr.
Izdano: (2018)

Enhancement of adeno-associated viral (AAV) gene therapy using hydroxychloroquine in murine and human tissues
od: Chandler, L, i dr.
Izdano: (2019)

Adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes
od: McClements, M, i dr.
Izdano: (2017)

The biological activity of AAV vectors for choroideremia gene therapy can be measured by in vitro prenylation of RAB6A
od: Patrício, M, i dr.
Izdano: (2018)

Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola
od: Tan, T, i dr.
Izdano: (2017)

AAV2/2-CBA-REP1 Vector with WPRE Provides Functional Expression of the Transgene in Choroideremia Mouse Knock-Out and Patient Cells
od: Tolmachova, T, i dr.
Izdano: (2012)

Adeno-associated virus vectors for gene therapy /
od: Flotte, T. R., i dr.
Izdano: (2005)

Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors.
od: Handa, A, i dr.
Izdano: (2000)

Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors
od: Handa, A, i dr.
Izdano: (2000)

Visual acuity after retinal gene therapy for Choroideremia
od: Edwards, T, i dr.
Izdano: (2016)

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
od: Han, RC, i dr.
Izdano: (2021)

Prenylation of rab6a as a potency assay for choroideremia gene therapy
od: Patricio, M, i dr.
Izdano: (2017)

Technique of retinal gene therapy: delivery of viral vector into the subretinal space
od: Xue, K, i dr.
Izdano: (2017)

Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
od: Xue, K, i dr.
Izdano: (2018)

Retinal gene therapy in patients with choroideremia: Initial fi ndings from a phase 1/2 clinical trial
od: MacLaren, R, i dr.
Izdano: (2014)

Ocular gene therapy for choroideremia: clinical trials and future perspectives
od: Xue, K, i dr.
Izdano: (2018)

Macular hole surgery in patients with end-stage choroideremia.
od: Zinkernagel, MS, i dr.
Izdano: (2013)

The spectrum of CHM gene mutations in choroideremia and their relationship to clinical phenotype
od: Simunovic, M, i dr.
Izdano: (2016)

Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo.
od: Tolmachova, T, i dr.
Izdano: (2013)

Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo
od: Tolmachova, T, i dr.
Izdano: (2013)

Macular hole surgery in patients with end-stage choroideremia
od: Zinkernagel, MS, i dr.
Izdano: (2013)

Impact of vital dyes on cell viability and transduction efficiency of AAV vectors used in retinal gene therapy surgery: an in vitro and in vivo analysis
od: Salvetti, A, i dr.
Izdano: (2017)

Adeno‐associated viral vectored delivery of a monoclonal antibody gene against blood‐stage malaria
od: Bardelli, M, i dr.
Izdano: (2019)

A fragmented adeno-associated viral dual vector strategy for treatment of diseases caused by mutations in large genes leads to expression of hybrid transcripts
od: McClements, M, i dr.
Izdano: (2016)

Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.
od: Maclaren, R, i dr.
Izdano: (2014)

Functional defects in color vision in patients with choroideremia
od: Jolly, J, i dr.
Izdano: (2015)

Gene therapy for surfactant protein B deficiency using recombinant AAV vectors
od: Meyer-Berg, H
Izdano: (2021)

Characterizing the natural history of visual function in choroideremia using microperimetry and multimodal retinal imaging
od: Jolly, J, i dr.
Izdano: (2017)

Promoter orientation within an AAV-CRISPR vector affects Cas9 expression and gene editing efficiency
od: Fry, LE, i dr.
Izdano: (2020)

Adeno-associated viral vectored delivery of a novel monoclonal antibody gene against blood-stage Plasmodium falciparum malaria
od: Bardelli, M, i dr.
Izdano: (2018)

A qualitative and quantitative assessment of fundus autofluorescence patterns in patients with choroideremia
od: Jolly, J, i dr.
Izdano: (2016)

Production of AAV vectors for gene therapy : a cost-effectiveness and risk assessment
od: Rodríguez Pinhao Miessner, Diego
Izdano: (2016)

Cell-mediated inflammatory response to AAV gene therapy in the retina
od: Chandler, LC, i dr.
Izdano: (2020)

Correlation of optical coherence tomography and autofluorescence in the outer retina and choroid of patients with choroideremia
od: Xue, K, i dr.
Izdano: (2016)

In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration.
od: Buch, P, i dr.
Izdano: (2006)

Gene therapy using viral vector against anxiety
od: Loo, Sze Jie
Izdano: (2016)

Viral vectors for gene therapy : methods and protocols /
od: Machida, Curtis A.
Izdano: (2003)

An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4−/− mice
od: McClements, ME, i dr.
Izdano: (2018)

Optimizing an AAV-CRISPR system for retinal gene therapy
od: Stevanovic, M
Izdano: (2019)

Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
od: Chandler, LC, i dr.
Izdano: (2021)